Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Rebonuputemcel

Source date not recordedAnalyse record ↗

Disc-derived progenitor cell therapy in a recruiting Phase 3 study for symptomatic lumbar degenerative disc disease.

Modality
allogeneic injectable disc-derived progenitor cell therapy
Availability (US)
Phase 3 PIVOT study Recruiting; parallel confirmatory program planned
Biomarkers
low-back-pain visual analogue scale; Oswestry Disability Index; adverse events; disc structural imaging
Hallmark targeted
stem cell exhaustion, extracellular-matrix degeneration, impaired tissue regeneration
Kind
investigational cell therapy
Clinical trials
NCT07254806 — Phase 3 PIVOT, Recruiting on September 23, 2026 registry update